Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IntelliDOT names new chairman and CEO
Mr Sweeney has been founder and CEO of eight healthcare service companies including Bridge Medical, a provider of bedside barcode scanning for medication administration, and CardioNet, a developer
Mr Sweeney has been founder and CEO of eight healthcare service companies including Bridge Medical, a provider of bedside barcode scanning for medication administration, and CardioNet, a developer
Avineuro said that the results of the Phase I studies are expected to be available in May 2009. Based on these and other results, Avineuro Pharmaceuticals plans to
Prior to his retirement from Bristol-Myers Squibb (BMS), Dr Smyth led oncology medical affairs in the US, including the US life-cycle development of paclitaxel (Taxol), carboplatin (Paraplatin) and
The assays have been developed by Nuvera and the University of Texas MD Anderson Cancer Center. The Nuvera test portfolio will also be capable of reporting status of
The Series B financing will be used to accelerate the company’s investment in sales and marketing to meet the demand for i-FACTOR products outside the US as well
Under the agreement, which was announced in November 2008, AstraZeneca receives approximately $220 million for the divestiture. The over-the-counter (OTC) brands, predominantly sold in Sweden, include analgesics Alvedon
China Biologic Products, a plasma-based biopharmaceutical company, has reported a net income of $11.98m, or $0.56 per diluted share, for 2008, an increase of 46.5%, compared to $8.18m,
In addition, the companies have established oncology collaboration for two Bristol-Myers Squibb products – Sprycel (dasatinib) and Ixempra (ixabepilone). Under terms of the agreement Bristol-Myers Squibb will pay
Pursuant to Prescription Drug User Fee Act guidelines, Santarus expects the FDA will complete its review or otherwise respond to the new drug application (NDA) by December 4,
For the full year 2008, the company reported a net loss and comprehensive loss of $25.99 million, or $1.35 per share, compared to a net loss and comprehensive